Compare PGEN & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | ADNT |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | PGEN | ADNT |
|---|---|---|
| Price | $4.16 | $21.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 10 |
| Target Price | $7.67 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 5.7M | 1.1M |
| Earning Date | 11-13-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,309,000.00 | ★ $14,535,000,000.00 |
| Revenue This Year | $342.78 | $1.49 |
| Revenue Next Year | $478.46 | $2.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.20 | N/A |
| 52 Week Low | $1.05 | $10.04 |
| 52 Week High | $5.23 | $26.16 |
| Indicator | PGEN | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 68.69 |
| Support Level | $4.39 | $18.96 |
| Resistance Level | $4.95 | $20.72 |
| Average True Range (ATR) | 0.31 | 0.61 |
| MACD | -0.01 | 0.26 |
| Stochastic Oscillator | 22.06 | 98.59 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.